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DOI 10.1016/j.ccr.2011.04.018SUMMARYEukaryotic Initiation Factor 6 (eIF6) controls translation by regulating 80S subunit formation. eIF6 is overex-
pressed in tumors. Here, we demonstrate that eIF6 inactivation delays tumorigenesis and reduces tumor
growth in vivo. eIF6+/mice resist toMyc-induced lymphomagenesis and have prolonged tumor-free survival
and reduced tumor growth. eIF6+/ mice are also protected by p53 loss. Myc-driven lymphomas contain
PKCbII and phosphorylated eIF6; eIF6 is phosphorylated by tumor-derived PKCbII, but not by the eIF4F acti-
vator mTORC1. Mutation of PKCbII phosphosite of eIF6 reduces tumor growth. Thus, eIF6 is a rate-limiting
controller of initiation of translation, able to affect tumorigenesis and tumor growth. Modulation of eIF6
activity, independent from eIF4F complex, may lead to a therapeutical avenue in tumor therapy.INTRODUCTION
Ribosome biogenesis and translation are the sequential pro-
cesses that underlie the massive process of protein synthesis
(Sonenberg and Hinnebusch, 2009). The increased demand of
ribosomes, as detected by enlarged argyrophilic nucleoli, has
been demonstrated to be an independent prognostic marker
for malignancy (Montanaro et al., 2008). Increased rates of
protein synthesis have been associated with cell growth and
transformation (Silvera et al., 2010). This said, alterations in the
ribosomal machinery have been considered for a long time
only a by-product of transformation and tumor growth. This
view was challenged in recent years by genetic evidence
demonstrating that ribosomal alterations modulate tumorigen-
esis to an unexpected extent. Unfortunately, general rules are
difficult to extrapolate from genetic studies. In some circum-Significance
The translational machinery is an attractive target for cancer t
and regulated by the growth factor signaling pathway. For inst
mRNAs, is involved in cell cycle progression, and is activat
pathway, like rapamycin analogs (rapalogs), are used in cance
tion. Unfortunately, many cancer cells are insensitive to rapalo
that are controlled by growth factor activation, but not bymTOR
eIF6 is a potential target for cancer therapy, in alternative to estances, insufficiency of either ribosomal proteins or of trans-
acting factors in ribosome biogenesis results in increased
susceptibility to cancer, in spite of reduced growth capability.
This is evident in Diamond-Blackfan anemia or Swachmann-
Diamond syndrome, where depletion of ribosomal proteins and
a trans-acting factor in nucleolar biogenesis, respectively,
increases the risk of hematological malignancy, in the presence
of reduced growth (Narla and Ebert, 2010). It is unclear whether
this paradoxical effect is due to reduced immune surveillance or
to increased cell autonomous genetic instability. Alternatively,
increased cancer susceptibility in the presence of altered ribo-
somal production may be due to abnormal selection of trans-
lated mRNAs, as in the case of dyskeratosis congenita (Yoon
et al., 2006). In other cases, reduced growth due to haploinsuffi-
ciency of ribosomal proteins limits tumorigenesis, as in the
case of rpL24 deficiency in mice, which limits Myc-inducedherapy. Initiation factors (IFs) are rate-limiting in translation
ance, eIF4F complex is essential for translation of structured
ed by PI3K-mTOR stimulation. Drugs targeting the mTOR
r treatment and explicate their action impairing eIF4F forma-
gs. We searched for IFs that are rate limiting for translation
. eIF6 fulfills these conditions.We provide data showing that
IF4F.
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eIF6 Activity in Cancerlymphomagenesis (Barna et al., 2008). In this case, the protec-
tive effect of rpL24 deficiency is counterbalanced by skeletal
abnormalities, retinal degeneration, retarded growth, and mela-
nocyte deficits (Oliver et al., 2004). In conclusion, the unpredict-
able results of ribosomal depletion and the difficulty to pharma-
cologically inhibit ribosomal proteins render the targeting of
ribosome biogenesis, likely, unfeasible.
The fine-tuning of gene expression and the use of ribosomes in
conditions of demanded growth are coordinated by translational
control in the cytoplasm (Sonenberg and Hinnebusch, 2009).
Translational control in the cytoplasm is relevant to cancer
because it shapes the expression pattern of a given cell through
regulation of its protein synthesis rate and the selection of the
mRNAs to be translated. In addition, the growth factor signaling
pathways, which are always activated in cancer cells, have
translation factors as their final effectors (Silvera et al., 2010).
Thus, activated translation factors may be a valuable target in
cancer therapy. Initiation of translation is the rate-limiting step
of protein synthesis and is regulated by initiation factors (IFs)
(Jackson et al., 2010).
Initiation of translation requires three sequential steps: (1)
formation of 43S preinitiation complex by binding of ternary
complex eIF2-GTP-tRNAiMet to the 40S ribosomal subunit; (2)
formation of 48S preinitiation complex by binding of 43S subunits
to mRNA, assisted by the cap binding complex eIF4F; (3) forma-
tion of active 80S ribosome by recruitment of free 60S subunits.
Of these three steps, eIF4F formation has attracted a strong
interest in cancer biology because of experimental evidence
indicating its targetability and its activation by growth factors
(Sonenberg, 2008). eIF4F complex controls 48S formation by
favoring binding of mRNAs to the 40S and unwinding of their
50 UTRs, downstreamof growth factor activation.Notably, several
mRNAs involved in cell cycle progressionhave structured 50 UTRs
anddependoneIF4F for their efficient translation. Elegant genetic
and biochemical studies have shown that eIF4F complex forma-
tion is critically dependent from mTOR kinase activity and con-
stitutes an important rate-limiting step in tumor growth. Specifi-
cally, the cap binding protein eIF4E in the eIF4F complex is
inhibited by 4E-BPs. Blockers of mTOR complex 1 (mTORC1)
kinase activity cause dephosphorylation of 4E-BPs, which, in its
dephosphorylated form, binds and sequesters the cap binding
protein eIF4E (Sonenberg and Hinnebusch, 2009). The net result
of mTORC1 inhibitors (such as rapamycin) is the impairment of
eIF4F formation (Petroulakis et al., 2006). This mechanism has
gatheredgenetic andbiochemical evidence, and ispharmacolog-
ically exploited by rapalogs that block mTORC1 or by ATP site
mTOR inhibitors (Dowling et al., 2010; Hsieh et al., 2010; Ruggero
et al., 2004;Wendel et al., 2004). A drawbackof this strategy is the
relative insensitivity to rapalogs, as reported in vitro on several
cancer cell lines and in patients in vivo. This insensitivity may
have several causes including mutations in the Ras pathway
(Di Nicolantonio et al., 2010). In line with this, we suggested the
presence of rapamycin-insensitive translational regulation stimu-
lated by either protein kinase C (PKC) and Ras activators (Grosso
et al., 2008) or by adhesion to extracellular matrix (Gorrini et al.,
2005). For this reason, thediscoveryof targetable initiation factors
that act on mTORC1 independent mechanisms can be useful.
Most of the proteins that have been identified in the context of
ribosome biogenesis do not have a role in translation and vice766 Cancer Cell 19, 765–775, June 14, 2011 ª2011 Elsevier Inc.versa (Miluzio et al., 2009). Eukaryotic Initiation Factor 6 (eIF6)
is an exception because it is necessary for ribosome biogenesis
in the nucleolus (Sanvito et al., 1999; Si and Maitra, 1999) and it
can act as a translation factor in the cytoplasm (Gandin et al.,
2008). eIF6 activity regulates the availability of functional 60S
ribosomes. 40S ribosomal subunits can bind 60S subunits in
the absence of mRNA generating an inactive 80S complex.
eIF6 biochemical activity prevents the association between
40S subunit, not loaded with mRNA, and free 60S subunits.
eIF6 activity, by preventing premature 80S formation, therefore
allows the presence of a pool of free ribosomes in the cytoplasm
(Ceci et al., 2003; Valenzuela et al., 1982). The cytoplasmic
activity of eIF6 is peculiar because it is dispensable for transla-
tion in vitro (Pestova et al., 1998, 2000). However, in eIF6 haploin-
sufficient cells, where reduction of cytoplasmic eIF6 occurs,
basal protein synthesis is normal, but insulin or phorbol ester-
stimulated synthesis is abrogated. We have previously shown
that eIF6 is highly expressed in human cancer (Sanvito et al.,
2000) and fibroblasts with reduced eIF6 levels cannot be effi-
ciently transformed by oncogenes in vitro (Gandin et al., 2008).
Here, we address the question whether eIF6 cytoplasmic
expression and activation are important for in vivo tumorigen-
esis, and whether eIF6 inactivation results in reduced tumor
growth.
RESULTS
Delayed Lymphomagenesis by Restriction
of Myc-Independent eIF6 Expression
We previously generated eIF6 knockout mice and showed that
eIF6 heterozygous (eIF6+/) mice are normal with the exception
of reduced fat accumulation (Gandin et al., 2008). To understand
how eIF6 affects tumorigenesis and tumor growth in vivo, we
selected the Em-Myc lymphomamodel. In this model, expression
of theMyconcogene in theBcell lineagedrivesa lethal lymphoma
with a median survival of 3 months (Iritani and Eisenman, 1999)
and associated with increased translation rate and upregulation
of eIF4E (Ruggero et al., 2004). Myc-induced lymphomagenesis
is reduced by ribosomal protein rpL24 haploinsufficiency (Barna
et al., 2008) and increased by eIF4E overexpression (Ruggero
et al., 2004). Thus, this model is ideal for evaluating the relative
strength by which eIF6 modulates tumorigenesis in comparison
to the other members of the translational machinery.
We crossed eIF6+/ mice with Em-Myc mice to generate Em-
Myc/eIF6+/+ and Em-Myc/eIF6+/ mice. Myc-induced lympho-
magenesis results in a 2-fold increase in eIF6 protein levels,
both in wild-type and eIF6+/ mice (Figure 1A), confirming that
upregulation of eIF6 is part of the oncogenic process. However,
Em-Myc/eIF6+/+ expressed more eIF6 than Em-Myc/eIF6+/ indi-
cating that gene dosage is a strong determinant of eIF6 expres-
sion. To establish whether eIF6 upregulation was directly depen-
dent on Myc, we infected primary fibroblasts with an inducible
MYC gene. Two-fold overexpression of Myc did not change
eIF6 protein levels, whereas it increased eIF4E (Figure 1B). We
investigated this further by overexpressing Myc using retroviral
infection under the control of LTR elements, which increased
Myc mRNA 5-fold, eIF4E mRNA 3-fold, but eIF6 mRNA only
around 10% (see Figure S1 available online). These data suggest
that, different from other members of the translational machinery
Figure 1. eIF6 Is a Myc-Independent Trans-
lation Factor Required for Rapid Myc-
Induced Lymphomagenesis
(A) Representative results of western blot analysis
on control mice and tumors from Em-Myc mice.
(B) Western blot analysis on eIF6+/+ and eIF6+/
MEFs expressing MycER, in the absence or
presence of OHT. Corresponding densitometric
analysis, normalized to actin levels, is indicated.
(C) Kaplan-Meier curves of Em-Myc/eIF6+/ mice
(n = 82) compared with the Em-Myc/eIF6+/+
animals (n = 106). ***p < 0.0001.
(D) Weight of spleens and lymph nodes of Em-Myc
mice. *p < 0.05 and **p < 0.01.
See also Figure S1 and Table S1.
Cancer Cell
eIF6 Activity in Cancer(Ruggero, 2009), eIF6 expression is, at most, weakly regulated
by Myc.
Em-Myc/eIF6+/ survived longer than Em-Myc/eIF6+/+ mice
(Figure 1C). At 200 days, when virtually all Em-Myc/eIF6+/+
mice had succumbed to the disease, 40% of Em-Myc/eIF6+/
mice were still alive. Maximal survival of Em-Myc/eIF6+/ mice
was more than 14 months, when mice were sacrificed in the
absence of signs of disease. One early sign of lymphomagenesis
is the enlargement of the spleen, due to extramedullary hemo-
poiesis, and of the lymph nodes due to expansion of tumor cells.
The spleen of nontransgenics eIF6+/ and eIF6+/+ mice were
identical, while the spleen of Em-Myc/eIF6+/+ was grossly
enlarged (Table S1). Two-month-old Em-Myc/eIF6+/ mice
showed little splenomegaly and lymph node enlargement, sug-
gesting a retard in tumorigenesis (Figure 1D). However, the
size of lymph nodes and spleen was identical for 3-month-old
Em-Myc/eIF6+/+ and Em-Myc/eIF6+/ mice (Figure 1D). In pretu-
moral mice, spleen enlargement was due to increased prolifera-
tion and extramedullary hematopoiesis (Figures 2A and 2B), the
latter being less developed in Em-Myc/eIF6+/ than in wt. The
reduction in extramedullary hematopoiesis of Em-Myc/eIF6+/
mice was confirmed by lowered expression of hematopoietic
GATA-1 transcription factor in the spleen of heterozygous mice
than in wt mice (Figure 2C; Figure S2).
In summary, splenomegaly of Em-Myc/eIF6+/was delayed for
30 days compared with wt mice, due to reduced extramedullaryCancer Cell 19, 765–7hematopoiesis, indicating a delay in the
onset of lymphomas. In contrast, the
survival of Em-Myc/eIF6+/ mice com-
pared with Em-Myc/eIF6+/+ mice was
more than doubled. These two facts sug-
gested that eIF6 haploinsufficiency limits
both tumor onset and growth, which
was further investigated.
Reduced Expression of eIF6
Protects from p53 Loss without
Affecting Apoptosis
p53 deletion accelerates Em-Myc-driven
lymphomagenesis by suppressing Myc-
induced apoptosis. Since a small nucle-
olar pool of eIF6 is necessary for biogen-
esis of the ribosomal 60S subunit (Gandinet al., 2008; Sanvito et al., 1999), and haploinsufficiency of ribo-
somal proteins causes ‘‘ribosomal stress’’ and p53 induction
(Zhang and Lu, 2009), we investigated whether p53 is required
for the antitumorigenic effect of eIF6 haploinsufficiency in the
Em-Myc model. In general, phenotypes due to ribosomal stress
are reverted by p53 deletion (Zhang and Lu, 2009). No induction
of p53 was seen in eIF6+/ mice (Figures S3A and S3B). The
protective effect of eIF6 heterozygosity was observed also in
the p53+//Em-Myc mice (Figure 3A). To investigate whether
eIF6 acted in the antiapoptotic pathway in pre-B cells, we
purified them from several pretumoral 4-week-old mice and
analyzed apoptosis. Early activation of Myc led to a strong
increase in apoptosis, which was not statistically affected by
eIF6 haploinsufficiency (Figure 3B). The spleens of 4-week-old
p53+//eIF6+/ mice showed reduced proliferation compared
with that of p53+//eIF6+/+ mice (Figures S3C–S3E).
eIF6 Reduction Impairs Cell Cycle Progression of Pre-B
Cells and Both Myc- and LPS/Interleukin 4-Induced
Global Translation
To investigate the potential mechanism by which eIF6 reduction
delays lymphomagenesis, we analyzed proliferation and differen-
tiationofpre-B lymphocytes fromcontrol andEm-Mycmice.Pre-B
cells from Em-Myc mice had a higher percentage of S-phase
cells as compared with nontransgenics (Figure 4A). eIF6 het-
erozygosity caused a statistically significant reduction in the75, June 14, 2011 ª2011 Elsevier Inc. 767
Figure 2. Em-Myc/eIF6+/– Mice Show Reduced Splenomegaly at
Early Stages of Disease
(A) Representative staining of spleens of 4-week-old Em-Myc mice. Spleen
morphology was analyzed with H&E staining, while proliferating cells were
detected by anti-PCNA antibody. Changes in proliferation rate involve
primarily the spleen red pulp (as shown in insets). Hemopoiesis in spleens was
analyzed with an anti GATA1 antibody. Scale bar is indicated.
(B) Percentage of PCNA-positive cells in the spleens of 4-week-old mice.
(C) Western blot analysis for eIF6 and GATA1 in spleen extracts. Densitometric
analysis is shown.
See also Figure S2.
Figure 3. Em-Myc/eIF6+/– Mice Are Protected Also by p53 Depletion,
without Affecting Apoptosis
(A) Kaplan-Meier curves of p53+//Em-Myc/eIF6+/ mice (n = 24) compared
with p53+//Em-Myc/eIF6+/+ ones (n = 21). ***p < 0.001.
(B) TUNEL assay on purified pre-B lymphocytes from spleens and bone
marrow (n = 3 per genotype).
See also Figure S3.
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ure 4A). In Em-Myc mice, B cell development is characterized by
a reduction ofmatureB cells and increase of pre-B cells (Langdon
et al., 1986). We did not see a significant change in the percent-
ages of mature and immature B cells in Em-Myc/eIF6+/+ mice,
compared to Em-Myc/eIF6+/ mice (Figure 4B). Taken together,
data suggest that eIF6 impacts on cell cycle control downstream
multiple oncogenic events such as Myc and p53 (see above).
In mouse fibroblasts, eIF6 heterozygosity impairs growth
factor and PMA-stimulated translation (Gandin et al., 2008).
Myc oncogenesis was shown to increase the translational rate
(Barna et al., 2008; Iritani and Eisenman, 1999). Thus, we evalu-
ated how eIF6 haploinsufficiency impacts translation of purified
pre-B cells, using methionine incorporation assay. Myc over-768 Cancer Cell 19, 765–775, June 14, 2011 ª2011 Elsevier Inc.expression caused an increase in methionine incorporation.
eIF6 haploinsufficiency reduced both Myc-induced and LPS/
IL4-induced translation (Figure 4C). These data demonstrate
that in conditions of mitogenic signaling eIF6 is rate-limiting for
translation in pre-B cells.
The PKCbII-eIF6 Axis Is Active in Lymphomas
To gain an insight on how the translation activity of eIF6 modu-
lates the tumorigenesis process, we exploited its activation
properties. RACK1, a ribosomal scaffold protein and intracellular
PKC receptor, interacts with eIF6 and modulates its capability
to keep ribosomal subunits dissociated (Ceci et al., 2003).
PKCbII is the most effective PKC isoform binding RACK1 (Steb-
bins andMochly-Rosen, 2001). Ser235 of eIF6 is phosphorylated
in vivo upon pharmacological stimulation of PKC and is found
phosphorylated in cycling cells (Dephoure et al., 2008). Conse-
quently, we examined whether lymphomas and pretumoral B
cells expressed PKCbII and whether this expression could be
Figure 4. eIF6 Reduction AffectsMycOnco-
genesis by Reducing Pre-B Cell Prolifera-
tion and Methionine Incorporation
(A) FACS analysis on primary pre-B lymphocytes
isolated from spleens and bone marrow of
4-week-old control mice (c) and Em-Myc mice
(Myc), previously injected i.p. with 1 mg BrdU
(n = 3 per genotype). *p < 0.05 and **p < 0.01.
(B) Development of B cells. B cells of 4-week-old
mice isolated from spleen and bone marrow of
control (c) mice and Em-Myc ones (Myc). Total
bone marrow lymphocytes were stained with
FITC-anti-mouse B220 and PE-anti-mouse IgM,
while total spleen cells were stained with FITC-
anti-mouse IgD and PE-anti-mouse IgM; nuclei
were counterstained with PI marker and all
samples were analyzed by FACS. Data are ex-
pressed in percentages (n = 3).
(C) Representative results of 35S-methionine
labeling experiment in purified pre-B lymphocytes
either unstimulated or upon stimulation with LPS/
IL4.
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in pretumoral B cells already in 4-week-old mice (Figure S4A)
and later in all lymphomas (Figure 5A). We immunoprecipitated
mTOR and PKCbII from lymphomas and assayed their capability
to phosphorylate eIF6. eIF6 was not phosphorylated by mTOR,
while 4E-BP1 was (Figure 5B). In the same condition, PKCbII
immunoprecipitated from lymphomas phosphorylated eIF6, as
well as its control substrate MARCKS1 (Figure 5C). PKCbII
activity was already evident in pretumoral samples of 4-week-
old mice (Figures S4B–S4D). Next, we assayed by 2D-gel anal-
ysis whether endogenous eIF6 was phosphorylated in
lymphomas; eIF6 from lymphomas showed 3 spots compatible
with phosphorylation (Figure 5D). In summary, data show that
PKCbII is abundant in lymphomas and can phosphorylate eIF6
in vitro and in vivo. Since Ser235 is the only consensus site for
PKCbII phosphorylation, we addressed its role in translation,
tumorigenesis, and tumor growth.
Mutated eIF6 Abrogates Tumorigenesis In Vivo
We analyzed the relevance of Ser235 phosphorylation in trans-
formation and tumor growth in wt and eIF6 heterozygous cells.Cancer Cell 19, 765–7We transformed wt and eIF6+/ primary
fibroblasts using DNp53 + H-rasV12,
eIF6+/ fibroblasts transformed at lower
efficiency than do wt cells (Figure 6A; Fig-
ure S5A). Similar to what we saw in Myc-
driven lymphomagenesis, eIF6+/ trans-
formed cells expressed lower levels of
eIF6 than do wt cells (Figure 6B). We then
proceeded to conduct reconstitution
experiments. Transformed primary fibro-
blasts were reconstituted as follows: (1)
eIF6+/ cells with either eIF6 wt, eIF6 S235A
or control GFP, and (2) wt fibroblasts with
either eIF6 S235A or control GFP. Analysis
of the levelsof eIF6 ineachpopulation indi-
cated that each constructwasmildly over-expressed (Figure 6C). Reconstitution of eIF6+/ fibroblasts with
wt eIF6 increased their anchorage-independent colony formation,
whereas the reconstitutionwitheIF6S235Adecreased it (Figure6D).
Similarly, wt eIF6 fibroblasts expressing eIF6 S235A showed
a reduction of the transformation rate (Figure 6D). Similar results
were obtained in primary fibroblasts transformed with Myc + H-
rasV12 (Figure S5B). Taken together, these data imply that eIF6
levels affect transformation in vitro and that mutation of Ser235
reduces, but not abolishes, the rate of transformation. We evalu-
ated global translation of MEFs transformed by Myc + H-rasV12
and found that the translational rate of cells expressing eIF6S235A
reduced considerably during transformation (Figure 6E).
Next, we injected equal numbers of transformedMEFs in nude
mice. We found that transformed eIF6 wt fibroblasts grew faster
than do their eIF6+/ counterpart (Figure 7A). Furthermore, the
expression of eIF6S235A in both transformed wt eIF6 (Figure 7B)
and eIF6+/ cells (Figure 7C) reduced the growth of tumors. In
transformed eIF6+/ cells, the re-expression of wt eIF6 acceler-
ated tumor growth (Figure 7C). We analyzed morphology, prolif-
eration, apoptosis, and angiogenesis in tumor xenografts.
Tumors expressing wild-type levels of eIF6 had more BrdU75, June 14, 2011 ª2011 Elsevier Inc. 769
Figure 5. eIF6 Is Phosphorylated in Myc-
Driven Lymphomas Expressing PKCbII
(A) Lymphomas express PKCbII. Representative
western blot of proteins recovered from tumors of
Em-Myc mice presenting comparable weight.
(B and C) Kinase assay on tumor samples at
indicated conditions. eIF6 is directly phosphory-
lated by PKCbII (C), but not by mTOR (B). Corre-
sponding densitometric analyses were normalized
to background and appropriate controls indicated.
(D) Representative 2D gel electrophoresis of
a lymphoma sample: black arrows indicate eIF6.
See also Figure S4.
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7D and 7E). Compared with wt, eIF6+/ tumors also presented
reduced cellular density (Figure 7E; Figure S6). We did not detect
differences in the apoptotic rate between wt and eIF6+/ tumors,
as determined by TUNEL and caspase 3 stainings, and both
tumor types presented sporadic clusters of apoptotic cells in
necrotic or infiltrated areas (Figure S6). In addition, eIF6+/
tumors show fewer CD31-positive cells. In conclusion, Ser235
of eIF6 is not essential for normal growth, but it is important for
transformation and for growth of tumor cells, in vivo.
DISCUSSION
We have presented evidence that eIF6 activation is rate-limiting
in tumorigenesis and tumor growth in vivo. We showed that
eIF6+/ mice are resistant to lymphomagenesis also in condi-
tions of p53 haploinsufficiency, suggesting that the protective
effect is independent from ribosomal stress. We found that
PKCbII, but not mTORC1, phosphorylates eIF6, suggesting
that eIF6 activity is not under mTOR control. Since eIF6 haploin-
sufficiency has limited or no negative side effects, we hypothe-
size that eIF6 would be an attractive therapeutic target for treat-
ing tumors, in particular, those insensitive to mTOR inhibition.
Upstream Regulation of eIF6
Understanding the transcriptional network regulating eIF6
expression is important to definewhich oncogenes could control
eIF6 during the process of tumorigenesis. It has been proposed
that Myc acts as a master regulator of translational control, by
affecting multiple targets that are rate limiting in translation (Rug-
gero, 2009; White, 2008). Myc regulates the expression of genes
of the eIF4F complex, which are necessary for cap-dependent770 Cancer Cell 19, 765–775, June 14, 2011 ª2011 Elsevier Inc.translation and for efficient translation
of structured mRNAs like cyclin D (Rug-
gero, 2009). These data suggest that
Myc evolved as a powerful transcriptional
regulator affecting the translation of spe-
cific classes of mRNAs.
Our data show that eIF6 is not directly
regulated by the oncogene Myc. In the
past, we showed that eIF6 expression is
regulated by transcription factor complex
GA-binding protein (GABP) (Donadini
et al., 2006). GABP regulates the expres-sion of nuclear genes involved in mitochondrial respiration (Ris-
tevski et al., 2004). In addition, among GABP targets there are
also ribosomal proteins (Perry, 2005). Thus, GABP may regulate
the transcription of genes of the ribosomal and the mitochondrial
machineries upon increased needs of metabolic rates. So far,
a role for GABP in tumorigenesis has not been described.
Considering that GABP may have an essential role in mediating
the proliferative response, it will be of interest to define if some
oncogenes directly act on GABP expression.
Finally, the strong gene dosage effect of eIF6may suggest that
in some conditions, tumor cells may have an advantage to
amplify eIF6 gene. In this sense, amplification of the 20q11.2
has been reported in myelodispastic syndrome and acute
myeloid leukemya (Mackinnon and Campbell, 2007), but specific
studies on eIF6 gene are lacking.
Downstream Targets of eIF6: Are They Specific or Not?
The specific effect of eIF6 haploinsufficiency in restricting tumor-
igenesis without obvious negative side effects is remarkable. In
heterozygous mice, the only phenotype we could observe was
a nonpathogenic reduction in liver mass and in adipose tissue
(Gandin et al., 2008). This observation raises the question on
whether eIF6 regulates the translation of specific mRNAs.
Studies on eIF6+/ cells expressing Myc or with inactivated
p53 showed a delay in G1/S phase progression suggesting
that specific mRNAs involved in cell cycle progression can be
affected at the level of translation. Thus, at first sight proliferating
cells seem more sensitive to eIF6 depletion. Expression data
support this hypothesis; eIF6 is enriched in the stem cell and
proliferating compartment of colonic epithelium (Sanvito et al.,
2000) and is generally highly expressed in embryonic and epithe-
lial tissues (Biffo et al., 1997). Furthermore, we found that
Figure 6. eIF6 Haploinsufficiency andMuta-
tion of eIF6S235A Reduce Transformation
and Protein Synthesis
(A) Transformation rate of wt and eIF6+/ fibro-
blasts with indicated retroviruses (n = 6).
(B) eIF6 levels were determined by western blot-
ting in wt and heterozygous eIF6 transformed
cells. Anti H-Ras antibody was used as a control
for retroviral infection.
(C) Western blot analysis of eIF6 levels in eIF6wt
and eIF6S235A transduced cells. Anti H-Ras and
anti-GFP antibody were used as a control for
retroviral and lentiviral infection, respectively.
(D) Transformation assay on eIF6+/+ and eIF6+/
primary fibroblasts transformed with DNp53 plus
H-rasV12. Both genotypes were then infected with
lentivirus carrying GFP as an internal control and
mutant eIF6S235A, while eIF6+/ MEFs received
also a lentivirus bearing full-length eIF6 (eIF6wt) to
rescue normal eIF6 protein levels. Single retroviral
infections are indicated as a control (100%). (n = 6
per genotype).
(E) 35S-methionine incorporation on MEFs cells
sequentially infected with lentiviral vector expres-
sing either GFP, as control, or mutated eIF6 S235A,
followed by retrovirus bearing Myc + H-rasV12
oncogenes. Methionine incorporation was
measured before retroviral infection with Myc + H-
rasV12 (left), 3 days after retroviral infection
(middle), and 10 days after retroviral infectionwhen
cells showed signs of transformation (right).
Results are expressed in percentage of control.
See also Figure S5.
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in conditions of eIF6 haploinsufficiency (Gandin et al., 2008),
suggesting that mRNAs involved in the mitogenic response
and glucose metabolism are more susceptible to changes in
eIF6 levels.Figure 7. eIF6 Reduction and Mutation of eIF6S235A Reduce Tumor Gro
(A–C) Subcutaneous injection of transformed eIF6+/+ and eIF6+/ MEFs with DNp
n = 6 for B and C).
(D and E) Proliferation rate was measured by BrdU incorporation. Quantificat
(D). Corresponding representative immunohistochemical staining (E). Scale bar i
See also Figure S6.The molecular mechanism by which eIF6 regulates translation
is to prevent improper 80S complex formation. eIF6 binds, in
a regulated fashion, 60S subunits, preventing their association
with 40S subunits that are not loaded with mRNA. This mecha-
nism allows the presence of a pool of free ribosomes in thewth in Xenograft
53 plus H-rasV12 (DN) reconstituted with either wt eIF6 or eIF6S235A (n = 3 for A,
ion was performed setting at 100% the values of control mice; **p < 0.01
s indicated.
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Figure 8. Model of eIF6 Activation
Growth factors activate PKC. In our model, eIF6 is phosphorylated by PKCbII
on Ser235, the only consensus site for PKCbII phosphorylation; eIF6 activity is
modulated by PKC, resulting in increased translation and tumorigenesis.
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eIF6 Activity in Cancercytoplasm (Ceci et al., 2003; Valenzuela et al., 1982). Since eIF6
binds 60S subunits, it is not expected to actively select for
mRNAs for translation. In principle, there are two possible
mechanisms by which eIF6 could affect the translation of
specific mRNAs. One, indirectly, by reducing available 60S,
eIF6 haploinsufficiency generates a strong competition
between mRNA-loaded 48S subunits, which may lead to a
competitive disadvantage for some mRNAs. In this case, it
will be difficult to identify specific mRNAs affected, but rather
it is expected the narrowing of the translational landscape, as
recently suggested for eIF4G depletion (Park et al., 2011). In
this context, it would be interesting to study whether inhibition
of eIF6 acts synergistically to 4E-BP dephosphorylation, which
affects the translation of eIF4F-dependent mRNAs. A second
possibility is that eIF6 regulates the translation of a specific
class of mRNAs. Myc-hyperactivation increases cap-depen-
dent translation and reduces translation of IRES-containing
mRNAs, whereas deficiency of large ribosomal protein rpL24
reverts IRES translation, at mitosis, and reduces lymphomagen-
esis (Barna et al., 2008). The mechanism by which eIF6 acts is,
however, very different from rpL24 because eIF6 haploinsuffi-
ciency limits not only Myc-induced translation, but also growth
factor-induced translation. Indeed, eIF6 haploinsufficiency also
restricts proliferation in conditions of p53 depletion, thus resem-
bling a general translation node regulating cell cycle progres-
sion. In addition, we have not observed in eIF6 heterozygous
cells changes in the translation efficiency of HCV and Myc
IRES reporters. Further work to identify specific mRNA targets
is required.
eIF6 Broadens Cancer Treatment as Target
of the Translational Machinery
A growing interest has risen regarding translational control as
a determinant of cancer tumorigenesis and as a pharmacologi-
cally targetable process (Silvera et al., 2010; Sonenberg and
Hinnebusch, 2009). There are more than 20 initiation factors
(Jackson et al., 2010), but only eIF4F complex formation has
reached sufficient genetic and pharmacological evidence to
be an important target in cancer (Hsieh et al., 2010; Ruggero
et al., 2004;Wendel et al., 2004). eIF4F targeting can be obtained
through mTOR inhibition using rapalogs (Robert and Pelletier,
2009) or ATP site mTOR inhibitors (Feldman et al., 2009; Hsieh
et al., 2010; Janes et al., 2010). More recently, blockers of
eIF4E/eIF4G interaction (Moerke et al., 2007) or eIF4A have
also been proposed (Cencic et al., 2010). Due to the fact that
eIF4F inhibition acts exclusively at the level of 48S formation,
and that resistance to mTORC1 inhibition may be reverted by
activation of the Ras pathway (Di Nicolantonio et al., 2010), it
may be of value to target other steps of initiation that are under
growth factor activation and are rate limiting. For this, eIF6 is
particularly attractive because its activity is independent from
mTORC1 phosphorylation, but specific to conditions of growth
factor activation.
Phosphorylation of Ser 235 is important for protumorigenic
activity of eIF6 (Figure 8). The phosphorylation of eIF6 is stimu-
lated by agonists of phorbol esters, hence of PKC and of the
Ras cascade (Ceci et al., 2003). Tumor-derived PKCbII phos-
phorylates Ser235 of eIF6, in vitro. A clear mechanistic role of
eIF6 phosphorylation in vivo is not available, whereas, in vitro,772 Cancer Cell 19, 765–775, June 14, 2011 ª2011 Elsevier Inc.phosphorylation of Ser235 causes release of eIF6 from 60S
(Ceci et al., 2003), which presumably is a necessary step for
60S activation. PKCbII is the preferred partner of RACK1,
a PKC receptor shown to be part of ribosomal particles (Sen-
gupta et al., 2004). PKCbII is upregulated in human lymphomas
and its upregulation is linked to poor outcome in B cell malignan-
cies (Chaiwatanatorn et al., 2009; Schaffel et al., 2007). PKCb
inhibition reduces translation without affecting mTORC1 targets
(Grosso et al., 2008). Taken together these observations suggest
a role for the PKC axis in the regulation of translation, in condi-
tions of elevated growth factor signaling. Enzastaurin is a
PKCb inhibitor with a broad range of inhibition in tumor cell lines
and is currently being evaluated in clinical trials against
lymphomas (Leonard et al., 2008). It will be interesting to define
if part of the action of enzastaurin is through inhibition of eIF6
activity.
The binding activity of eIF6 to ribosomes is well defined and
amenable to the development of high-throughput screenings
for agonists/antagonists. However, our knowledge of the eIF6
molecular mechanism is still too limited to predict the effects
of agonists or antagonists of eIF6 binding to the 60S. Theoreti-
cally, antagonists of eIF6 binding to 60S should be effective
blockers of eIF6 function. All these hypotheses must be now
experimentally addressed.
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Mice
All experiments were approved by the Ethical Committee of San Raffaele and
comply with E.C. regulations (IACUC authorization SK397). eIF6+/ mice were
generated as previously described (Gandin et al., 2008), and backcrossed to
C57BL6/N strain for a minimum of eight generations. eIF6+/, p53/, and
Em-Myc transgenic mice were intercrossed to obtain the genotypic combina-
tions, as described in the manuscript. Mice were monitored daily for the tumor
development until they died spontaneously or were sacrificed if showing
evident signs of distress. Kaplan-Meier curve was used to examine the survival
rate of all considered animals. Cervical, axillary, and inguinal lymph nodes and
spleens of thesemice were recovered, weighted, and used for further analysis.
Eight-week-old CD1 athymic nudemice were used for detecting tumor growth
after a subcutaneous (s.c.) injection of transformed MEFs cells, as indicated in
this paper. Mice with tumors larger than 600 mm3 were sacrificed. Genotyping
of the offspring mice was detected by PCR using AmpliTaq Gold (Roche)
according to the manufacturer’s protocol. The PCR primers for genotyping
of eIF6 and Em-Myc transgenic mice were previously reported (Gandin et al.,
2008; Gorrini et al., 2007); p53 genotyping was performed using the specific
primers: 50-ACAGCGTGGTGGTACCTTAT-30 (wt allele), 50-TATACTCAGAG
CCGGCCT-30 (common primer), and 50-CTATCAGGACATAGCGTTGG-30
(mutant allele). PCR products were resolved on 2% agarose gels.
Antibodies and Reagents
The following antibodies were used: rabbit polyclonal antibodies against eIF6
(Biffo et al., 1997), c-Myc, Cleaved Caspase 3, RACK1 (Cell Signaling), PKCbII,
H-Ras (Santa Cruz), PCNA, GATA1 (Abcam); mouse monoclonal antibodies
against BrdU (Sigma), p53 (Cell Signaling), b-Actin (Sigma) and eIF6. LPS, IL4,
4-hydroxy-tamoxifen (OHT) and all powders and reagents were from Sigma.
Primary Cell Culture
Primary MEFs were isolated from 13.5 d.p.c. embryos as previously described
(Gandin et al., 2008). Primary B lymphocytes were isolated from spleen and
bone marrow of 4-week-old mice by labeling with CD45R (B220) microbeads
and using an autoMACS separator (Milteny Biotec), according to manufac-
turer’s instruction and (Gorrini et al., 2007). All the analyses were performed
at least three times on different genetic backgrounds.
Cell cycle ratewas analyzed on freshly isolated B lymphocytes from 4-week-
old mice (eIF6+/+/Em-Myc and eIF6+//Em-Myc mice). These mice received
1 mg of BrdU (Sigma) by intraperitoneal (i.p.) injection 2 hr before being sacri-
ficed. Primary B lymphocytes were recovered from spleen and bone marrow,
fixed in 95% ethanol, and labeled with FITC-conjugated anti-BrdU, using the
BD Biosciences BrdU Flow Kit, following manufacturer’s instructions. B
lymphocytes development was examined by labeling specific surface markers
with FITC-anti-mouse IgD, FITC-anti-mouse B220, and PE-anti-mouse IgM
(BD Pharmingen). Nuclei were counterstained with propidium iodide (PI)
marker. For both analyses, 10,000 events per tube were acquired by BD
FACSCANTO II flow cytometer and then analyzed using the FCS Express soft-
ware (BD). The apoptotic rate was alsomeasured on the same cells. B lympho-
cytes were fixed in paraformaldehyde, permeabilized, and stained using In Situ
Cell Death Detection Kit, AP (Roche), following the manufacturer’s instruc-
tions. All the results were expressed as percentage and each experiment
was done in triplicate.
Translation Analysis
Cells were pulsed with 35S-labeled methionine (Perkin-Elmer) for 30 min, in the
tested conditions. Cells were lysed in 50 ml of RIPA buffer without SDS (10 mM
Tris-HCl [pH 7.5], 1%Na-deoxycholate, 1% Triton X-100, 150mMNaCl, 1mM
EDTA, protease inhibitor cocktail). Aliquots of 10 ml of extracts were TCA-
precipitated on glass microfiber filters (Whatman) and counted. Obtained
values were normalized on viable cell number. Each sample was performed
in triplicate.
Histological Staining, Immunohistochemistry, and In Situ TUNEL
Assay
Immunohistochemical and histological analysis were performed on paraffin-
embedded sections obtained from spleens of eIF6+/+/Em-Myc, eIF6+//Em-Myc, and p53+/ mice and from tumors derived from nude mice. Hematoxylin
and eosin staining (H&E) was performed on all tissues for morphological anal-
ysis, while immunohistochemistry for the considered targets was done using
the Vectastain Elite ABC kit (Vector), according to the manufacturer’s instruc-
tions. Apoptotic cells were identified on tumor sections using a commercially
available In Situ Cell Death Detection Kit, AP (Roche), according to manufac-
turer’s protocol.
Transformation Analysis
Primary fibroblasts were infected at early passage with a retrovirus carrying
both Myc and DNp53 + oncogenic H-rasV12 as previously described (Gandin
et al., 2008). After 2 days these cells were also infected with lentiviral vectors.
The lentiviral vectors used in this study express full-length wt eIF6, mutant
eIF6S235A and GFP as internal control. Packaging plasmid VSV-G, PMDLg/
pRRE, pREV, and transfer vector pCCL-PPT-hPGK-pre used in this paper
was previously described and full-length wt eIF6, mutant eIF6S235A, and GFP
cloning was performed as previously described (Gandin et al., 2008). Foci
were counted 2–3 weeks after infections and transformed cells were recov-
ered for subcutaneous injection in nude mice (500,000 cells/mouse).
Kinase Assay
Proteins from Eu-Myc tumoral lymph nodes were extracted in lysis buffer
(50 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20, 13 Protease Inhibitors
(Sigma), 1 mM NaF, 10 mM b-glycerophosphate), clarified by centrifugation
and protein concentration was quantified by the BiCinchonic Acid (BCA)
protein assay (EuroClone). For PKC assays, lysates were subjected to pre-
clearing with Protein G (GE Healthcare) for 2 hr at 4C, and precleared protein
extracts were incubated with antibody against PKCbII (Santa Cruz Biotech-
nology) overnight at 4C using constant rotation. Immunoprecipitation was
performed with protein G for 2 hr. Beads were washed three times and resus-
pended in lysis buffer. The kinase assay was performed by adding 3 mg of eIF6
recombinant protein, 3 mg of recombinant RACK1 (Ceci et al., 2003), or 5 mg of
GST-MARCKS (Myristoylated Alanine-Rich C-Kinase Substrate (Soh and
Weinstein, 2003) in the PKCbII specific buffer (100 mM MgCl2, 10 mM
CaCl2, lipid mixture) either in the presence or absence of immunoprecipitated
PKCbII. mTOR kinase assay was instead performed by adding either 3 mg of
eIF6 or 5 mg of GST- 4E-BP1 recombinant protein to immunoprecipitated
mTOR in a specific buffer (10 mM HEPES, 50 mM b-glycerophosphate,
150 mM NaCl). The negative control was an immunoprecipitate obtained
with irrelevant antibodies.
Four mCi of g32-ATP (Perkin Elmer) were added to each sample. The reac-
tion was run at 30C for 1 hr and terminated by adding one volume of sample
buffer. The samples were boiled 5 min, separated by SDS-PAGE and stained
with Coomassie Brilliant blue R-250. Autoradiography was performed on dried
gels. Recombinant eIF6 was prepared in E. coli. N-terminal histidine tagged
human eIF6 was coexpressed with a mixture of molecular chaperones (de
Marco et al., 2007). Protein production was induced at 16C overnight and
the recombinant protein was first recovered by metal affinity chromatography.
Monomeric active eIF6 was separated by inactive, dimeric and aggregated
eIF6 by gel filtration. GST-4E-BP1 was a kind gift of Dr. C. Proud (University
of Southampton, UK).
Two-Dimensional Gel Electrophoresis
Tumor samples were examined in two-dimensional gel electrophoresis.
Samples were lysed in RIPA buffer and proteins were precipitated with 10%
Trichloroacetic acid. Pellets were resuspended in two-dimensional buffer
(7 M Urea, 2 M Thiourea, 50 mM DTT and 4% CHAPS) and 100 mg of proteins
were isoelectrofocused. The first dimensionwas performed onReadyStrip IPG
Strips (pH 3.9–5.1; Biorad) For the reduction/alkylation step, the strips were
incubated with re-equlibration buffer (50 mM Tris-HCl [pH 8.8], 6 M urea,
30% glycerol, 2% SDS, bromophenol blue) plus DTT and re-equilibration
buffer plus iodoacetamide, respectively.
Then, the strips were subjected to SDS/PAGE for the second dimension.
Proteins were transferred on PVDF membrane and subsequently incubated
with eIF6 monoclonal antibodies. The signal was detected with an anti-mouse
secondary antibody and ECL substrate kit (GE Healthcare). Each experimental
sample was run at least twice, and at least three different biological replicates
were analyzed.Cancer Cell 19, 765–775, June 14, 2011 ª2011 Elsevier Inc. 773
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Each experiment was repeated a minimum of three times, as biological repli-
cates; means and standard deviations between different experiments were
calculated. Statistical P-values obtained by Student t test were indicated:
three asterisks *** for p values less than 0.001, two asterisks ** for p values
less than 0.01 and one asterisk * for p values less than 0.05. Kaplan-Meier
curves were validated by the log-rank test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and one table and can be found
with this article online at doi:10.1016/j.ccr.2011.04.018.
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